TPM502

About Topas Therapeutics

Topas Therapeutics is a clinical-stage biotech pioneering a targeted approach to immune tolerance using its proprietary Topas Particle Conjugates (TPCs). The platform leverages liver sinusoidal endothelial cells (LSECs) to deliver disease-specific antigens, aiming to reprogram the immune system and induce durable, antigen-specific tolerance via regulatory T cells (Tregs). With clinical proof-of-concept established in a Phase 2a celiac disease trial, the company is preparing for a global Phase 2b study and is positioned to address a broad spectrum of autoimmune conditions with high unmet need. Its technology offers a potentially disease-modifying alternative to broad immunosuppression.

Therapeutic Areas

Other Celiac Disease Drugs